| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: ZGNX |
| Security Type |
Common Stock |
| Lead Underwriter |
Banc of America Securities LLC |
| Days In Registration |
134 |
| Date Filed |
20-Mar-2008 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Zogenix Inc, located in San Diego, California, manufactures pharmaceuticals with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Its lead product candidate, sumatriptan DosePro (TM) enables needle free delivery of subcutaneus sumatripan- the fastest migraine medicine. The second product candidate ZX002 is an oral controlled release formulation of hydrocodone for the treatment of chronic pain. The company was incorporated on May 11, 2006. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
- |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
